Cargando…

Apolipoprotein A‐IV concentrations and clinical outcomes in a large chronic kidney disease cohort: Results from the GCKD study

BACKGROUND: Chronic kidney disease (CKD) represents a chronic proinflammatory state and is associated with very high cardiovascular risk. Apolipoprotein A‐IV (apoA‐IV) has antiatherogenic, antioxidative, anti‐inflammatory and antithrombotic properties and levels increase significantly during the cou...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwaiger, Johannes P., Kollerits, Barbara, Steinbrenner, Inga, Weissensteiner, Hansi, Schönherr, Sebastian, Forer, Lukas, Kotsis, Fruzsina, Lamina, Claudia, Schneider, Markus P., Schultheiss, Ulla T., Wanner, Christoph, Köttgen, Anna, Eckardt, Kai‐Uwe, Kronenberg, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305919/
https://www.ncbi.nlm.nih.gov/pubmed/34914850
http://dx.doi.org/10.1111/joim.13437
_version_ 1784752433598038016
author Schwaiger, Johannes P.
Kollerits, Barbara
Steinbrenner, Inga
Weissensteiner, Hansi
Schönherr, Sebastian
Forer, Lukas
Kotsis, Fruzsina
Lamina, Claudia
Schneider, Markus P.
Schultheiss, Ulla T.
Wanner, Christoph
Köttgen, Anna
Eckardt, Kai‐Uwe
Kronenberg, Florian
author_facet Schwaiger, Johannes P.
Kollerits, Barbara
Steinbrenner, Inga
Weissensteiner, Hansi
Schönherr, Sebastian
Forer, Lukas
Kotsis, Fruzsina
Lamina, Claudia
Schneider, Markus P.
Schultheiss, Ulla T.
Wanner, Christoph
Köttgen, Anna
Eckardt, Kai‐Uwe
Kronenberg, Florian
author_sort Schwaiger, Johannes P.
collection PubMed
description BACKGROUND: Chronic kidney disease (CKD) represents a chronic proinflammatory state and is associated with very high cardiovascular risk. Apolipoprotein A‐IV (apoA‐IV) has antiatherogenic, antioxidative, anti‐inflammatory and antithrombotic properties and levels increase significantly during the course of CKD. OBJECTIVES: We aimed to investigate the association between apoA‐IV and all‐cause mortality and cardiovascular outcomes in the German Chronic Kidney Disease study. METHODS: This was a prospective cohort study including 5141 Caucasian patients with available apoA‐IV measurements and CKD. The majority of the patients had an estimated glomerular filtration rate (eGFR) of 30–60 ml/min/1.73m(2) or an eGFR >60 ml/min/1.73m(2) in the presence of overt proteinuria. Median follow‐up was 6.5 years. The association of apoA‐IV with comorbidities at baseline and endpoints during follow‐up was modelled adjusting for major confounders. RESULTS: Mean apoA‐IV concentrations of the entire cohort were 28.9 ± 9.8 mg/dl. Patients in the highest apoA‐IV quartile had the lowest high‐sensitivity C‐reactive protein values despite the highest prevalence of diabetes, albuminuria and the lowest eGFR. Each 10 mg/dl higher apoA‐IV translated into lower odds of prevalent cardiovascular disease (1289 cases, odds ratio = 0.80, 95% confidence interval [CI] 0.72–0.86, p = 0.0000003). During follow‐up, each 10 mg/dl higher apoA‐IV was significantly associated with a lower risk for all‐cause mortality (600 cases, hazard ratio [HR] = 0.81, 95% CI 0.73–0.89, p = 0.00004), incident major adverse cardiovascular events (506 cases, HR = 0.88, 95% CI 0.79–0.99, p = 0.03) and death or hospitalizations due to heart failure (346 cases, HR = 0.84, 95% CI 0.73–0.96, p = 0.01). CONCLUSIONS: These data support a link between elevated apoA‐IV concentrations and reduced inflammation in moderate CKD. ApoA‐IV appears to be an independent risk marker for reduced all‐cause mortality, cardiovascular events and heart failure in a large cohort of patients with CKD.
format Online
Article
Text
id pubmed-9305919
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93059192022-07-28 Apolipoprotein A‐IV concentrations and clinical outcomes in a large chronic kidney disease cohort: Results from the GCKD study Schwaiger, Johannes P. Kollerits, Barbara Steinbrenner, Inga Weissensteiner, Hansi Schönherr, Sebastian Forer, Lukas Kotsis, Fruzsina Lamina, Claudia Schneider, Markus P. Schultheiss, Ulla T. Wanner, Christoph Köttgen, Anna Eckardt, Kai‐Uwe Kronenberg, Florian J Intern Med Original Articles BACKGROUND: Chronic kidney disease (CKD) represents a chronic proinflammatory state and is associated with very high cardiovascular risk. Apolipoprotein A‐IV (apoA‐IV) has antiatherogenic, antioxidative, anti‐inflammatory and antithrombotic properties and levels increase significantly during the course of CKD. OBJECTIVES: We aimed to investigate the association between apoA‐IV and all‐cause mortality and cardiovascular outcomes in the German Chronic Kidney Disease study. METHODS: This was a prospective cohort study including 5141 Caucasian patients with available apoA‐IV measurements and CKD. The majority of the patients had an estimated glomerular filtration rate (eGFR) of 30–60 ml/min/1.73m(2) or an eGFR >60 ml/min/1.73m(2) in the presence of overt proteinuria. Median follow‐up was 6.5 years. The association of apoA‐IV with comorbidities at baseline and endpoints during follow‐up was modelled adjusting for major confounders. RESULTS: Mean apoA‐IV concentrations of the entire cohort were 28.9 ± 9.8 mg/dl. Patients in the highest apoA‐IV quartile had the lowest high‐sensitivity C‐reactive protein values despite the highest prevalence of diabetes, albuminuria and the lowest eGFR. Each 10 mg/dl higher apoA‐IV translated into lower odds of prevalent cardiovascular disease (1289 cases, odds ratio = 0.80, 95% confidence interval [CI] 0.72–0.86, p = 0.0000003). During follow‐up, each 10 mg/dl higher apoA‐IV was significantly associated with a lower risk for all‐cause mortality (600 cases, hazard ratio [HR] = 0.81, 95% CI 0.73–0.89, p = 0.00004), incident major adverse cardiovascular events (506 cases, HR = 0.88, 95% CI 0.79–0.99, p = 0.03) and death or hospitalizations due to heart failure (346 cases, HR = 0.84, 95% CI 0.73–0.96, p = 0.01). CONCLUSIONS: These data support a link between elevated apoA‐IV concentrations and reduced inflammation in moderate CKD. ApoA‐IV appears to be an independent risk marker for reduced all‐cause mortality, cardiovascular events and heart failure in a large cohort of patients with CKD. John Wiley and Sons Inc. 2022-01-04 2022-05 /pmc/articles/PMC9305919/ /pubmed/34914850 http://dx.doi.org/10.1111/joim.13437 Text en © 2021 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Schwaiger, Johannes P.
Kollerits, Barbara
Steinbrenner, Inga
Weissensteiner, Hansi
Schönherr, Sebastian
Forer, Lukas
Kotsis, Fruzsina
Lamina, Claudia
Schneider, Markus P.
Schultheiss, Ulla T.
Wanner, Christoph
Köttgen, Anna
Eckardt, Kai‐Uwe
Kronenberg, Florian
Apolipoprotein A‐IV concentrations and clinical outcomes in a large chronic kidney disease cohort: Results from the GCKD study
title Apolipoprotein A‐IV concentrations and clinical outcomes in a large chronic kidney disease cohort: Results from the GCKD study
title_full Apolipoprotein A‐IV concentrations and clinical outcomes in a large chronic kidney disease cohort: Results from the GCKD study
title_fullStr Apolipoprotein A‐IV concentrations and clinical outcomes in a large chronic kidney disease cohort: Results from the GCKD study
title_full_unstemmed Apolipoprotein A‐IV concentrations and clinical outcomes in a large chronic kidney disease cohort: Results from the GCKD study
title_short Apolipoprotein A‐IV concentrations and clinical outcomes in a large chronic kidney disease cohort: Results from the GCKD study
title_sort apolipoprotein a‐iv concentrations and clinical outcomes in a large chronic kidney disease cohort: results from the gckd study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305919/
https://www.ncbi.nlm.nih.gov/pubmed/34914850
http://dx.doi.org/10.1111/joim.13437
work_keys_str_mv AT schwaigerjohannesp apolipoproteinaivconcentrationsandclinicaloutcomesinalargechronickidneydiseasecohortresultsfromthegckdstudy
AT kolleritsbarbara apolipoproteinaivconcentrationsandclinicaloutcomesinalargechronickidneydiseasecohortresultsfromthegckdstudy
AT steinbrenneringa apolipoproteinaivconcentrationsandclinicaloutcomesinalargechronickidneydiseasecohortresultsfromthegckdstudy
AT weissensteinerhansi apolipoproteinaivconcentrationsandclinicaloutcomesinalargechronickidneydiseasecohortresultsfromthegckdstudy
AT schonherrsebastian apolipoproteinaivconcentrationsandclinicaloutcomesinalargechronickidneydiseasecohortresultsfromthegckdstudy
AT forerlukas apolipoproteinaivconcentrationsandclinicaloutcomesinalargechronickidneydiseasecohortresultsfromthegckdstudy
AT kotsisfruzsina apolipoproteinaivconcentrationsandclinicaloutcomesinalargechronickidneydiseasecohortresultsfromthegckdstudy
AT laminaclaudia apolipoproteinaivconcentrationsandclinicaloutcomesinalargechronickidneydiseasecohortresultsfromthegckdstudy
AT schneidermarkusp apolipoproteinaivconcentrationsandclinicaloutcomesinalargechronickidneydiseasecohortresultsfromthegckdstudy
AT schultheissullat apolipoproteinaivconcentrationsandclinicaloutcomesinalargechronickidneydiseasecohortresultsfromthegckdstudy
AT wannerchristoph apolipoproteinaivconcentrationsandclinicaloutcomesinalargechronickidneydiseasecohortresultsfromthegckdstudy
AT kottgenanna apolipoproteinaivconcentrationsandclinicaloutcomesinalargechronickidneydiseasecohortresultsfromthegckdstudy
AT eckardtkaiuwe apolipoproteinaivconcentrationsandclinicaloutcomesinalargechronickidneydiseasecohortresultsfromthegckdstudy
AT kronenbergflorian apolipoproteinaivconcentrationsandclinicaloutcomesinalargechronickidneydiseasecohortresultsfromthegckdstudy
AT apolipoproteinaivconcentrationsandclinicaloutcomesinalargechronickidneydiseasecohortresultsfromthegckdstudy